×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
NYSE:GKOS

Glaukos Stock Forecast, Price & News

$45.74
+0.13 (+0.29%)
(As of 06/29/2022 04:00 PM ET)
Add
Compare
Today's Range
$44.74
$45.76
50-Day Range
$34.86
$61.26
52-Week Range
$33.33
$86.35
Volume
7,643 shs
Average Volume
472,423 shs
Market Capitalization
$2.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.56
30 days | 90 days | 365 days | Advanced Chart

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock Forecast (MarketRank)

Overall MarketRank

2.01 out of 5 stars

Medical Sector

590th out of 1,432 stocks

Surgical & Medical Instruments Industry

69th out of 137 stocks

Analyst Opinion: 3.1Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Glaukos logo

About Glaukos (NYSE:GKOS)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

GKOS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
727
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
6/29/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$58.56
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+28.0%
Consensus Rating
Hold
Rating Score (0-4)
2.22222222222222
Research Coverage
9 Analysts

Profitability

Net Income
$-49.59 million
Pretax Margin
-9.32%

Debt

Sales & Book Value

Annual Sales
$294.01 million
Book Value
$12.52 per share

Miscellaneous

Free Float
43,500,000
Market Cap
$2.17 billion
Optionable
Optionable
Beta
1.53














Glaukos Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos
or view top-rated stocks.

What is Glaukos' stock price forecast for 2022?

9 Wall Street research analysts have issued 1 year target prices for Glaukos' stock. Their GKOS stock forecasts range from $34.00 to $105.00. On average, they predict Glaukos' stock price to reach $58.56 in the next twelve months. This suggests a possible upside of 28.0% from the stock's current price.
View analysts' price targets for Glaukos
or view top-rated stocks among Wall Street analysts.

How has Glaukos' stock performed in 2022?

Glaukos' stock was trading at $44.44 at the beginning of the year. Since then, GKOS shares have increased by 2.9% and is now trading at $45.74.
View the best growth stocks for 2022 here
.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Glaukos
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) issued its quarterly earnings data on Wednesday, May, 4th. The medical instruments supplier reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.14. The medical instruments supplier had revenue of $67.70 million for the quarter, compared to analysts' expectations of $60.85 million. Glaukos had a negative net margin of 9.45% and a negative trailing twelve-month return on equity of 7.95%. Glaukos's revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.21) EPS.
View Glaukos' earnings history
.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $270.00 million-$275.00 million, compared to the consensus revenue estimate of $270.49 million.

Who are Glaukos' key executives?

Glaukos' management team includes the following people:
  • Mr. Thomas William Burns, Chairman & CEO (Age 61, Pay $1.96M)
  • Mr. Joseph E. Gilliam, Pres & COO (Age 45, Pay $991.52k) (LinkedIn Profile)
  • Mr. Chris M. Calcaterra, Exec. VP of Global Commercial Operations (Age 62, Pay $1M)
  • Dr. Mory Gharib Ph.D., Co-Founder
  • Mr. Alex R. Thurman, Sr. VP & CFO (Age 52)
  • Mr. Christopher William Lewis, VP of Investor Relations & Corp. Affairs
  • Ms. Diane W. Biagianti, Sr. VP & Gen. Counsel (Age 62)
  • Ms. Diana A. Scherer, VP of Compliance & Deputy Gen. Counsel
  • Ms. Michele M. Allegretto, Sr. VP of HR
  • Mr. David S. Haffner, Sr. VP of New Technologies

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.02%), Wellington Management Group LLP (9.93%), State Street Corp (3.55%), Riverbridge Partners LLC (1.35%), Polar Asset Management Partners Inc. (1.21%) and Northern Trust Corp (1.15%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos
.

Which institutional investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Renaissance Technologies LLC, Assenagon Asset Management S.A., Rhenman & Partners Asset Management AB, Exchange Traded Concepts LLC, Goldman Sachs Group Inc., Connor Clark & Lunn Investment Management Ltd., and Northern Trust Corp. Company insiders that have sold Glaukos company stock in the last two years include Joseph E Gilliam, and William J Phd Link.
View insider buying and selling activity for Glaukos
or view top insider-selling stocks.

Which institutional investors are buying Glaukos stock?

GKOS stock was bought by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Dimensional Fund Advisors LP, Vanguard Group Inc., Citigroup Inc., Riverbridge Partners LLC, Jane Street Group LLC, Essex Investment Management Co. LLC, and Bank of America Corp DE.
View insider buying and selling activity for Glaukos
or or view top insider-buying stocks.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $45.74.

How much money does Glaukos make?

Glaukos (NYSE:GKOS) has a market capitalization of $2.17 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49.59 million in net income (profit) each year or ($0.610010) on an earnings per share basis.

How many employees does Glaukos have?

Glaukos employs 727 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for Glaukos is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at [email protected], or via fax at 949-367-9984.

This page (NYSE:GKOS) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.